Colorectal cancer (CRC) is among the most common cancers in the developed world. With the average lifetime risk of developing CRC as high as 6%, CRC represents a major health burden in these societies.
screening and reimbursed by the national healthcare system. Similar to France, the National Health Service (NHS) in the UK aggressively promotes the use of standard FOBTs for screening by personal invitation, free supply of test kits to the homes of patients and other measures. However, colonoscopy is not reimbursed for primary screening, but used as a second-line screening modality after a positive FOBT. 6 Guidelines in the US recommend annual testing by FOBT and colonoscopies at 10-year intervals, with flexible sigmoidoscopies half-way between the colonoscopies. Screening with guideline-recommended methods is generally reimbursed provided that the patients have access to some kind of healthcare scheme. 7 Despite these recommendations and a multitude of measures to enforce them by healthcare providers, healthcare authorities and patient advocacy groups, the majority of CRCs continue to be diagnosed in advanced stages. 8, 9 Adherence to screening programmes remains a noticeable challenge: in Germany, ~3% of the target group per year accept a screening colonoscopy. Extrapolated to the recommended 10-year interval, more than 70% of the population between 55 and 65 years of age have never undergone a screening colonoscopy. 10 In the US, about 40% comply with recommendations to undergo screening by endoscopy in the recommended time interval.
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Non-invasive screening modalities would be potentially suitable to better motivate screened individuals to undergo a colonoscopy if they were accepted by the screening population. However, compliance to FOBT is estimated to be as low as 20% in Germany and 12% in the US. 10, 11 One reason for the low adherence specifically to FOBT screening may be the level of patient involvement. 
Blood-based Colorectal Cancer Screening with the Septin 9 Test

DNA Methylation of the Septin 9 Gene
In tumorigenesis, epigenetic alterations are among the early events that occur in cells changing from normal to tumour cells. Methylation of DNA, the addition of a methyl group to the 5' position of cytosine, defines one type ofepigenetic change that is frequently related to a change at the expression level of a gene. This has been well characterised in tumour biology in general, 12,13 and extensively described for CRC in particular. [14] [15] [16] Epigenomics has identified and validated DNA methylation of the This tumour-specific methylation pattern can be used to amplify specifically cell-free DNA shed into the bloodstream by tumour cells.
Since the development of a sensitive realtime polymerase chain reaction (PCR) assay, m SEPT9 performance has been verified in plasma specimens in multiple independent case-control studies (see Table 1 ). [18] [19] [20] In order to make m SEPT9 testing available to the general population,
Epigenomics has developed a CE-marked in vitro diagnostic (IVD)
test for reliable detection of m SEPT9 in a blood plasma specimen according to respective regulations for IVD products. This test reports the presence of m SEPT9 in a qualitative way for easy interpretation.
As the presence of m SEPT9 is strongly associated with the detection of invasive colorectal adenocarcinoma, a patient testing positive for m SEPT9 should undergo colonoscopy to confirm the diagnosis (see Figure 1 ). For patients who have a negative septin 9 test result, the 
Technological Principles of the Methylated Septin 9 Detection Test
The principle of detection of methylated septin 9 DNA consists of four steps (see Figure 2) , as detailed below.
Blood Sampling and Plasma Preparation
A 9-10ml blood sample is taken in the physician's office using pre-defined K 2 EDTA blood collection tubes and kept at 2-8ºC until collection by the laboratory courier, and is then transported refrigerated to the central laboratory. On delivery to the laboratory, but within 24 hours after the blood is taken, the blood plasma is separated by repeated centrifugation and stored at 2-8ºC for further processing.
DNA Extraction from Plasma
At the laboratory, cell-free DNA of about 3.5ml of plasma is captured, washed and concentrated using magnetic beads that are covered with a suitable DNA-binding matrix. In broad terms, binding buffer containing the magnetic beads is added to the plasma and incubated under agitation. The beads are captured using a magnet and the supernatant is discarded. The DNA attached to the beads is washed several times with a washing buffer and then eluted from the beads in a small volume of elution buffer. All reagents necessary for this step are provided by the Epi proColon™ Plasma DNA Preparation Kit.
Bisulphite Conversion and DNA Purification
By treating the DNA with a high concentration of bisulphite under denaturing conditions, unmethylated cytosin is converted into uracil, while methylated cytosin is unaffected. Thus, methylation patterns are converted into sequence information that can be interrogated by any technology that discriminates between sequences, including realtime PCR. The conversion is achieved by combining the DNA with the bisulphite reagent and a reaction buffer for an overnight incubation. After the incubation, the DNA is purified by a second DNA extraction using magnetic particles with a similar protocol to that used in the first extraction from blood plasma.
DNA Methylation Biomarker Detection via Realtime Polymerase Chain Reaction
An in vitro PCR assay for the qualitative detection of SEPT9 gene methylation uses Epigenomics' proprietary realtime PCR technologies HeavyMethyl and MethyLight. 21 The assay detects the previously 
Performance Characteristics of the Methylated Septin 9 Detection Test
Analytical Performance
To determine the limit of detection, a panel of three technical samples was tested. Two different concentrations (8 and 16pg/ml) of hydrolysed DNA detectable with the m SEPT9 PCR were spiked into a matrix containing genomic DNA at a concentration of 10ng/ml. A blank sample consisting of matrix with genomic DNA only and the two technical samples were processed with 24 replicates each, by three technicians.
Bisulphite-converted DNA was prepared using reagents from different lots of the Epi proColon Plasma DNA Preparation kit, and the converted DNA was assayed with Epi proColon realtime PCR kits from different lots adopting a schedule from NCCLS EP 17-A. 22 All 24 replicates of the blank sample were determined m SEPT9-negative and 23 replicates of the technical samples containing 8 and 16pg/ml DNA spikes were determined m SEPT9-positive. Table 2 summarises the data obtained. 23 Therefore, the detection limit of the assay is a concentration equivalent to as few as three genome copies per millilitre.
Reproducibility
The reproducibility of the procedure was tested by processing plasma aliquots from four pools generated from human ethylene diamine tetraacetic acid (EDTA) plasma. Two of the plasma pools comprised plasma from patients diagnosed with invasive colorectal adenocarcinoma. Two pools comprised plasma from patients with no apparent disease as controls. Both cancer pools were processed in nine replicates and both non-cancer pools were processed in 18 replicates. Processing of replicates was performed by three operators using different lots of the Epi proColon Plasma DNA Preparation kit (M5-01-001) and the Epi proColon realtime PCR kit. In 51 of the 54 m SEPT9 determinations, the expected result (cancer pool m SEPT9-positive; non-cancer pool m SEPT9-negative) was consistently generated. Table 2 summarises the results. 
PRESEPT
Conclusions and Outlook
The newly developed m SEPT9 early detection assay (Epi proColon) is the first CE-marked IVD assay for early detection of CRC in a blood plasma specimen. The design and robustness of the IVD assay enables its use in standard routine laboratory procedures. The convenience of the test for the patient and the PCP has the potential to improve patient compliance with CRC screening. The Epi proColon test now makes it possible to screen patients for CRC who might not otherwise be detected due to their denial of other screening modalities. What role this test will play in the concert of screening measures has to be determined after the results of the PRESEPT trial and further studies on compliance and cost-benefit. n
